Author

Kulchitskiy AR

Associate Professor, University of Maryland College Park - Cited by 6,752 - Targeting and Subcellular Transport of Drug Delivery Systems

Biography

Dr. Kulchitskiy Habil AR is currently working at Department of Heat Engines and Power Plants, Vladimir State University, Vladimir,Russia. His research interest includes Diesel, Particulate Matter, Test Driving Cycle. He is serving as an honorary reviewer for Advances in Automobile Engineering. He has authored of several research articles/books related to Diesel, Particulate Matter, Test Driving Cycle.
Title
Cited by
Year
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives
M Solomon, S MuroAdvanced drug delivery reviews 118, 109-134, 2017201
130
2017
Chitosan–Alginate Microcapsules Provide Gastric Protection and Intestinal Release of ICAM‐1‐Targeting Nanocarriers, Enabling GI Targeting In Vivo
R Ghaffarian, E Pérez‐Herrero, H Oh, SR Raghavan, S MuroAdvanced functional materials 26 (20), 3382-3393, 2016201
98
2016
A comparative study on the alterations of endocytic pathways in multiple lysosomal storage disorders
J Rappaport, RL Manthe, M Solomon, C Garnacho, S MuroMolecular pharmaceutics 13 (2), 357-368, 2016201
48
2016
Targeting superoxide dismutase to endothelial caveolae profoundly alleviates inflammation caused by endotoxin
VV Shuvaev, RY Kiseleva, E Arguiri, CH Villa, S Muro, ...Journal of Controlled Release 272, 1-8, 2018201
45
2018
Biodegradable “smart” polyphosphazenes with intrinsic multifunctionality as intracellular protein delivery vehicles
AP Martinez, B Qamar, TR Fuerst, S Muro, AK AndrianovBiomacromolecules 18 (6), 2000-2011, 2017201
39
2017
Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates
VV Shuvaev, S Muro, E Arguiri, M Khoshnejad, S Tliba, ...Journal of Controlled Release 234, 115-123, 2016201
38
2016
Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain
OA Marcos-Contreras, JS Brenner, RY Kiseleva, V Zuluaga-Ramirez, ...Journal of Controlled Release 301, 54-61, 2019201
35
2019
Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted nanocarriers in type B Niemann-Pick disease mice
C Garnacho, R Dhami, M Solomon, EH Schuchman, S MuroMolecular Therapy 25 (7), 1686-1696, 2017201
30
2017
Induced pluripotent stem cells for disease modeling and evaluation of therapeutics for Niemann-Pick disease type A
Y Long, M Xu, R Li, S Dai, J Beers, G Chen, F Soheilian, U Baxa, M Wang, ...Stem Cells Translational Medicine 5 (12), 1644-1655, 2016201
29
2016
Targeted carriers for intracellular drug delivery
S Muro-Galindo, VR MuzykantovUS Patent 9,707,9, 2017201
29
2017
Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance
J Kim, S Sinha, M Solomon, E Perez-Herrero, J Hsu, Z Tsinas, S MuroBiomaterials 147, 14-25, 2017201
26
2017
Alterations in cellular processes involving vesicular trafficking and implications in drug delivery
S MuroBiomimetics 3 (3), 19, 2018201
26
2018
How carrier size and valency modulate receptor-mediated signaling: understanding the link between binding and endocytosis of ICAM-1-targeted carriers
D Serrano, RL Manthe, E Paul, R Chadha, S MuroBiomacromolecules 17 (10), 3127-3137, 2016201
22
2016
ICAM‐1‐targeted nanocarriers attenuate endothelial release of soluble ICAM‐1, an inflammatory regulator
RL Manthe, S MuroBioengineering & translational medicine 2 (1), 109-119, 2017201
22
2017
Unprecedently high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers
N Roki, Z Tsinas, M Solomon, J Bowers, RC Getts, S MuroJournal of Controlled Release 305, 41-49, 2019201
17
2019
Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme
RL Manthe, M Loeck, T Bhowmick, M Solomon, S MuroJournal of Controlled Release 324, 181-193, 2020202
16
2020
Targeted protein replacement for the treatment of lysosomal storage disorders
SM Galindo, VR Muzykantov, EH SchuchmanUS Patent 9,655,953, 2017201
14
2017
DNA-based drug carriers: the paradox of a classical “cargo” material becoming a versatile “carrier” to overcome barriers in drug delivery
R Getts, S MuroCurrent pharmaceutical design 22 (9), 45-58, 2016201
12
2016
ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement
C Garnacho, S MuroJournal of drug targeting 25 (9-10), 786-795, 2017201
11
2017
Drug delivery across physiological barriers
S MuroCRC Press, 2016201
10
2016

Referred From: https://scholar.google.com/citations?user=--DTkMoAAAAJ&hl=en

Cited by
Citations 6752
h-index 45
i10-index 85
Recommended Journals
Open Access Journals